Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.

Faye Norby

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Rivaroxaban is a direct oral anticoagulant (DOAC) approved for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, a common arrhythmia. In this review, we summarize the effectiveness of rivaroxaban versus warfarin and the DOACs dabigatran, apixaban and edoxaban. The primary focus is on primary evidence from clinical trials, indirect comparison studies and real-world studies. While there are gaps in the literature, the evidence thus far indicates that rivaroxaban is superior to warfarin and similar to dabigatran, apixaban and edoxaban for the prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation, although rivaroxaban may be associated with an elevated bleeding risk compared with other DOACs.

Original languageEnglish (US)
Pages (from-to)549-560
Number of pages12
JournalJournal of Comparative Effectiveness Research
Volume12
Issue number9
DOIs
StatePublished - Sep 1 2017

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.'. Together they form a unique fingerprint.

Cite this